Ground Swell Capital’s Neurocrine Biosciences NBIX Stock Holding History

Ground Swell Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$496K	Buy	+3,767	New	+$500K	0.98%	22
2025 Q4	–	Sell	-4,017	Closed	-$564K	–	148
2025 Q3	$564K	Buy	+4,017	New	+$544K	1.23%	22
2021 Q4	–	Sell	-3,846	Closed	-$369K	–	95
2021 Q3	$369K	Buy	+3,846	New	+$363K	1.59%	16
2014 Q3	$2K	Buy	+150	New	+$2.24K	﹤0.01%	1916

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ground Swell Capital's NBIX Position: Q1 2026 in Review

Ground Swell Capital opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 3,767 shares worth $496K. The stake represents 0.98% of the portfolio and ranks #22 among its holdings. This is a return to the name: Ground Swell Capital previously reported a position in NBIX as recently as Q3 2025.

Ground Swell Capital first reported a position in NBIX in Q3 2014 and has held it in 4 quarters since. The position peaked at $564K in Q3 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Ground Swell Capital held 3,767 shares of Neurocrine Biosciences worth $496K as of Q1 2026.
Neurocrine Biosciences was a new Ground Swell Capital position in Q1 2026.
Neurocrine Biosciences made up 0.98% of Ground Swell Capital's portfolio in Q1 2026, its #22 holding.
Ground Swell Capital first reported a position in Neurocrine Biosciences in Q3 2014 and has held it in 4 quarters since.
Ground Swell Capital's Neurocrine Biosciences position peaked at $564K in Q3 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Ground Swell Capital's 13F filing for Q1 2026, filed 21 Apr 2026.